AskBorsa

SPINALEX results, Q1 2023

Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.

Net profit1.15 millionEGP · −41.5% vs the same period a year earlier
Total assets673 millionEGP · −2.0% vs the same period a year earlier
Shareholders' equity600 millionEGP · +6.0% vs the same period a year earlier
Operating cash flow7.06 millionEGP · +252.8% vs the same period a year earlier

In short

  • SPINALEX's net profit for Q1 2023 was about 1.15 million EGP, down −41.5% from 1.97 million EGP in Q1 2022.
  • Total assets at the end of Q1 2023 were about 673 million EGP, and shareholders' equity about 600 million EGP.
  • Operating cash flow for Q1 2023 was positive at 7.06 million EGP.
Source: the Q1 2023 financial statements

Key lines against the same period a year earlier

This periodQ1 2022Change
Net profit1.15 million1.97 million−41.5%
Gross profit7.41 million7.24 million+2.3%
Total assets673 million687 million−2.0%
Total liabilities72.95 million121 million−39.6%
Shareholders' equity600 million566 million+6.0%
Total liabilities and equity673 million687 million−2.0%
Operating cash flow7.06 million-4.62 million+252.8%
Investing cash flow11.26 million-7.42 million+251.7%
Financing cash flow-2.33 million-2.14 million−8.8%
Net change in cash15.98 million-14.18 million+212.7%

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.

Official report (PDF)All of SPINALEX's statements, five yearsAsk the AI analyst about SPIN

SPINALEX's Fiscal year 2026 results, the day they are published

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

Other periods for SPINALEX